KLK3 and prostate cancer: Ongoing trials featuring apalutamide include for neoadjuvant ADT prior to radical prostatectomy for patients diagnosed with localized high-risk prostate cancer (NCT03767244) and as part of a combination therapy for patients with rising PSA after radiation therapy and ADT (NCT03777982) or radical prostatectomy (NCT03141671).